14 completed, 1 unknown, 1 withdrawn. 16 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 16 | Completed 14, Unknown 1, Withdrawn 1 |
| Phase 2 | 1 | Withdrawn 1 |
Follow Interferon beta-1a: new trials by email Literature Review of Interferon beta-1a trials Research Report on Interferon beta-1a
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy Interferon Beta-1A, X-Ray Imaging, Echocardiography - Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Withdrawn | Fred Hutchinson Cancer Center | 2025-04-01 | 2024-07-12 | |
| Pharmacodynamic Biomarkers to Support Biosimilar Development: Interferon Beta-1A Products Interferon beta-1a, Peginterferon beta-1a, Placebo - Healthy Subjects, Pharmacokinetics | Phase 1 | Completed | Food and Drug Administration (FDA) | 84 | 2020-02-28 | 2024-04-22 |
| Pharmacokinetics and Pharmacodynamics of CinnoVex (Interferon Beta-1a) Compared to Avonex (Interferon Beta-1a) Interferon Beta-1A - Bioequivalence, Healthy | Phase 1 | Completed | Cinnagen | 40 | 2017-11-27 | 2020-01-10 |
| Immune- and miRNA-response to Recombinant Interferon Beta in Healthy Volunteers and Patients With Relapsing Remitting Multiple Sclerosis Rebif®, Avonex - Relapsing-remitting Multiple Sclerosis | Phase 1 | Unknown | PD Dr. Marcus Müller | 50 | 2015-01-01 | 2016-06-03 |
| Study to Evaluate the Pharmacokinetic Profiles of BIIB017 (Peginterferon Beta-1a) and Rebif® (Interferon Beta-1a) in Healthy Volunteers peginterferon beta-1a, Rebif - Multiple Sclerosis | Phase 1 | Completed | Biogen | 30 | 2014-10-01 | 2015-02-02 |
| Open Label Study of Tolerability, Pharmacokinetics and Pharmacodynamics of BCD-054 (Pegylated Interferon Beta-1a), IM and SC, Compared to Rebif® and Avonex® in Healthy Volunteers BCD-054, Rebif, Avonex - Healthy | Phase 1 | Completed | Biocad | 60 | 2014-07-01 | 2017-04-10 |
| Pharmacokinetics and Pharmacodynamics Study of BCD-033 Compared to Rebif® in Healthy Volunteers Interferon beta-1a - Healthy | Phase 1 | Completed | Biocad | 32 | 2013-02-01 | 2016-05-04 |
| Demonstrate the Bioequivalence of Interferon Beta-1a (INFB) Manufactured by Two Different Processes in Healthy Volunteers Interferon beta-1a (current approved manufacturing process invloving FBS), Interferon beta-1a (new process, manufactured without FBS) - Multiple Sclerosis | Phase 1 | Completed | Biogen | 110 | 2012-01-01 | 2012-11-19 |
| A Multiple-Dose, Open-Label, Phase 1, Pharmacokinetic, Pharmacodynamic, and Safety Study of Avonex® in Chinese Healthy Volunteer Subjects Avonex - Healthy | Phase 1 | Completed | Biogen | 24 | 2011-08-01 | 2011-11-04 |
| Pharmacokinetics and Pharmacodynamics of the Interferon Beta-1a Produced by Laboratorio Quimico Farmaceutico Bergamo Compared to Interferon Beta-1a (Rebif - Merck Serono) in Healthy Subjects Interferon beta-1a - Healthy | Phase 1 | Completed | Azidus Brasil | 20 | 2011-01-01 | 2013-02-25 |
| A Study of Avonex to Determine the Effects of Dose Titration on the Incidence of Flu Like Symptoms in Healthy Volunteers Avonex - Healthy Volunteers | Phase 1 | Completed | Biogen | 120 | 2010-05-05 | 2017-11-17 |
| Phase I BP Interferon (IFN) Beta-004 Interferon beta-1a HSA-free biosimilar, Interferon beta-1a HSA+ biosimilar, Interferon beta-1a original - Multiple Sclerosis, Relapsing-Remitting | Phase 1 | Completed | Centre Hospitalier Universitaire Vaudois | 24 | 2006-05-01 | 2015-08-10 |
| Phase I BP Interferon (IFN) Beta-001 Interferon beta-1a - Multiple Sclerosis, Relapsing-Remitting | Phase 1 | Completed | Centre Hospitalier Universitaire Vaudois | 12 | 2005-05-01 | 2015-08-06 |
| Safety Study of Interferon Beta 1a to for Acute Stroke Interferon beta-1a - Cerebrovascular Accident | Phase 1 | Completed | National Institute of Neurological Disorders and Stroke (NINDS) | 60 | 2004-11-17 | 2017-07-02 |
| A Bioequivalence Study of Serum Free Avonex and Serum Containing Avonex in Healthy Volunteers Serum containing Avonex, Serum Free Avonex - Multiple Sclerosis | Phase 1 | Completed | Biogen | 96 | 2003-08-01 | 2009-06-04 |
| Avonex®: Safety, Blood Levels and Effects Interferon beta 1a, (IM) AVONEX® - Multiple Sclerosis (MS) | Phase 1 | Completed | Trio Medicines Ltd. | 77 | 2001-01-01 | 2013-05-27 |
Multiple Sclerosis (4) · Multiple Sclerosis, Relapsing-Remitting (3) · Burkitt Lymphoma (1) · Inflammation (1) · Ischemia (1) · Lymphoma, B-Cell (1) · Lymphoma, Mantle-Cell (1) · Respiratory Aspiration (1) · Stroke (1)
Biogen (5) · Biocad (2) · Centre Hospitalier Universitaire Vaudois (2) · Azidus Brasil (1) · Cinnagen (1) · Food and Drug Administration (FDA) (1) · Fred Hutchinson Cancer Center (1) · National Institute of Neurological Disorders and Stroke (NINDS) (1) · PD Dr. Marcus Müller (1) · Trio Medicines Ltd. (1)
United States (6) · Russia (2) · Brazil (1) · China (1) · Finland (1) · Germany (1) · United Kingdom (1)
Ivan Sardaryan, PhD (2) · Carlos Sanabria, MD (1) · Jordan Gauthier (1) · Mika Scheinin, MD, PhD (1) · Steve Warrington (1)
PMID 27423899, PMID 21988668, PMID 26392348, PMID 27060836, PMID 41420638
2016 (1)